Announcements Trials
Browse Landscape

Phase

Phase 3 18Phase 2 6Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Hematologic Neoplasms 3Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Solid Tumors Harboring NTRK Fusion 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Locally Advanced Solid Tumors 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Has announcements × Parkinson Disease 4, Autosomal Dominant Lewy Body × Clear all
NCT02054806 2023-10-30

MK-3475-028

Merck Sharp & Dohme LLC

Phase 1 Completed
477 enrolled 14 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body

Data powered by HemOnc (CC BY 4.0) Colophon âš¡